PRKCE and acute myeloid leukemia: PKCε was found to be markedly overexpressed in patients with AML and positively correlated with reduced complete remission, disease-free survival, and enhanced resistance to the chemotherapeutic agent daunorubicin through P-glycoprotein (P-gp)-mediated drug efflux [43].